Superior products keep Smith & Nephew growing faster than rivals, says CEO (Chief Executive Officer)
This article was originally published in Clinica
It is now a year since UK group Smith & Nephew launched a takeover bid for Swiss rival Centerpulse. The bid failed when US giant Zimmer stepped in with a higher offer. Despite this disappointment, S&N CEO Sir Christopher O'Donnell reckons there are many reasons to be optimistic about the company's future. Interview by Eleanor Malone
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.